Synthetic adjuvants for vaccine formulations: phytol derivatives

Bibliography

• Nussbaum JC, Locksley RM. Infectious (Non)tolerance–frustrated commensalism gone awry? Cold Spring Harbor Perspect Biol 2012;4(5): a007328
   PubMed Web of Science ®Google Scholar
• Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med (New York, NY) 1937;37(3):509-13
   Google Scholar
• Straw BE, MacLachlan NJ, Corbett WT, Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine. Can J Comp Med 1985;49(2):149-51
   PubMedGoogle Scholar
• Moloney PJ, Fraser CJ. Immunization with diphtheria toxoid (Anatoxine Ramon). Am J Public Health (NY) 1927;17(10):1027-30
   PubMedGoogle Scholar
• Glenny AT, Pope C, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Path Bact 1926;29:38-45
   Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002;296(5566):301-5
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium adjuvants–in retrospect and prospect. Vaccine 2004;22(27-28):3658-68
   PubMed Web of Science ®Google Scholar
• Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol 2012;24(3):310-15
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33(4):492-503
   PubMed Web of Science ®Google Scholar
• Sercarz EE, Lehmann PV, Ametani A, Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-66
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91(3):295-8
   PubMed Web of Science ®Google Scholar
• Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect Biol 2012;4(3): pii: a006049
   PubMed Web of Science ®Google Scholar
• Leavy O. Vaccines: an effective PRR-targeting adjuvant in humans. Nat Rev Immunol 2011;11(12):801-1
   PubMedGoogle Scholar
• Mata-Haro V, Cekic C, Martin M, The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316(5831):1628-32
   PubMed Web of Science ®Google Scholar
• Tewari K, Flynn BJ, Boscardin SB, Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010;28(45):7256-66
   PubMed Web of Science ®Google Scholar
• Shukla NM, Salunke DB, Balakrishna R, Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer. PloS One 2012;7(8):e43612
   Google Scholar
• Didierlaurent AM, Morel S, Lockman L, AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183(10):6186-97
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6(5):723-39
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011;29(13):2461-73
   PubMed Web of Science ®Google Scholar
• Stills HF Jr. Adjuvants and antibody production: dispelling the myths associated with freund's complete and other adjuvants. ILAR J 2005;46(3):280-93
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30(1):16-34
   PubMed Web of Science ®Google Scholar
• Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007;76:447-80
   PubMed Web of Science ®Google Scholar
• McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol 2010;8:37
   PubMed Web of Science ®Google Scholar
• Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009;227(1):221-33
   PubMedGoogle Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11(5):373-84
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34(5):637-50
   PubMed Web of Science ®Google Scholar
• Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009;4:365-98
   PubMed Web of Science ®Google Scholar
• Kufer TA, Banks DJ, Philpott DJ. Innate immune sensing of microbes by Nod proteins. Ann N Y Acad Sci 2006;1072:19-27
   PubMed Web of Science ®Google Scholar
• Ryo A, Yamamoto N, Kojima Y, Vaccination with human induced pluripotent stem cells creates an antigen-specific immune response against HIV-1 gp160. Front Microbiol 2011;2:27
   Google Scholar
• Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012;28:137-61
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol 2011;187(2):597-602
   PubMed Web of Science ®Google Scholar
• Li H, Willingham SB, Ting JP-Y, Re F. cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181(1):17-21
   PubMed Web of Science ®Google Scholar
• Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 2010;40(3):616-19
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010;10(3):210-15
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Liu JL, Qu HP. Inflammasome and caspase-1 inhibition caused by Bcl-2 and Bcl-XL may influence cytokine responses of lipopolysaccharide-stimulated peripheral blood mononuclear cells from septic patients. Crit Care 2012;16(1):410
   PubMedGoogle Scholar
• Deng K, Adams MM, Damani P, Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine. Angew Chem Int Ed Engl 2008;47(34):6395-8
   PubMed Web of Science ®Google Scholar
• Shamshiev A, Donda A, Carena I, Self glycolipids as T-cell autoantigens. Eur J Immunol 1999;29(5):1667-75
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Roy C, Makowska A, Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000;12(2):211-21
   PubMed Web of Science ®Google Scholar
• Moody DB, Ulrichs T, Muhlecker W, CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 2000;404(6780):884-8
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012;30(29):4341-8
   PubMed Web of Science ®Google Scholar
• Aachoui Y, Ghosh SK. Immune enhancement by novel vaccine adjuvants in autoimmune-prone NZB/W F1 mice: relative efficacy and safety. BMC Immunol 2011;12:61
   PubMedGoogle Scholar
• Aachoui Y, Schulte ML, Fitch RW, Ghosh SK. Synthetic adjuvants for vaccine formulations: evaluation of new phytol derivatives in induction and persistence of specific immune response. Cell Immunol 2011;271(2):308-18
   PubMed Web of Science ®Google Scholar
• Gupta R. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998;32(3):155-72
   PubMed Web of Science ®Google Scholar
• Hutchison S, Benson RA, Gibson VB, Antigen depot is not required for alum adjuvanticity. FASEB J 2012;26(3):1272-9
   PubMed Web of Science ®Google Scholar
• Fehervari Z. No depot for alum. Nat Immunol 2012;13(5):437-7
   Google Scholar
• Flach TL, Ng G, Hari A, Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011;17(4):479-87
   PubMed Web of Science ®Google Scholar
• Kool M, Soullie T, van Nimwegen M, Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205(4):869-82
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Carneiro LA, Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003;300(5625):1584-7
   PubMed Web of Science ®Google Scholar
• Nizar S, Copier J, Meyer B, T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009;100(11):1697-703
   PubMed Web of Science ®Google Scholar
• Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res 2011;71(22):6915-20
   PubMed Web of Science ®Google Scholar
• Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22(5):347-52
   PubMed Web of Science ®Google Scholar
• Lin G, Wang J, Lao X, Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother 2012;35(4):337-43
   PubMed Web of Science ®Google Scholar
• Chowdhury RR, Ghosh SK. Phytol-derived novel isoprenoid immunostimulants. Front Immunol 2012;3:49
   PubMed Web of Science ®Google Scholar
• Reeves WH, Lee PY, Weinstein JS, Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009;30(9):455-64
   PubMed Web of Science ®Google Scholar
• Lattanzio G, Libert C, Aquilina M, Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997;151(3):689-96
   PubMed Web of Science ®Google Scholar
• Satoh M, Kuroda Y, Yoshida H, Induction of lupus autoantibodies by adjuvants. J Autoimmun 2003;21(1):1-9
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Nacionales DC, Akaogi J, Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004;58(5):325-37
   PubMed Web of Science ®Google Scholar
• Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981;290(5803):201-8
   PubMed Web of Science ®Google Scholar
• Chernomorsky S, Segelman A, Poretz RD. Effect of dietary chlorophyll derivatives on mutagenesis and tumor cell growth. Teratog Carcinog Mutagen 1999;19(5):313-22
   PubMedGoogle Scholar
• Hibasami H, Kyohkon M, Owaki S, Diol- and triol-types of phytol induce apoptosis in lymphoid leukemia Molt 4B cells. Int J Mol Med 2002;10(5):555-9
   PubMed Web of Science ®Google Scholar
• Gloerich J, van Vlies N, Jansen GA, A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARalpha-dependent and -independent pathways. J Lipid Res 2005;46(4):716-26
   PubMed Web of Science ®Google Scholar
• Goto T, Takahashi N, Hirai S, Kawada T. Various terpenoids derived from herbal and dietary plants function as ppar modulators and regulate carbohydrate and lipid metabolism. PPAR Res 2010;2010:483958
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Shimizu N, Kimura T, Polyunsaturated fats attenuate the dietary phytol–induced increase in hepatic fatty acid oxidation in mice. J Nutr 2006;136(4):882-6
   PubMed Web of Science ®Google Scholar
• Kagoura M MC, Morohashi M. Phytol is a novel tumor promoter on ICR mouse skin. Jpn J Cancer Res 1999;90(4):377-84
   PubMedGoogle Scholar
• Aachoui Y, Chowdhury RR, Fitch RW, Ghosh SK. Molecular signatures of phytol-derived immunostimulants in the context of chemokine-cytokine microenvironment and enhanced immune response. Cell Immunol 2011;271(2):227-38
   PubMed Web of Science ®Google Scholar
• Lim SY, Meyer M, Kjonaas RA, Ghosh SK. Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses. J Immune Based Ther Vaccines 2006;4:6
   PubMedGoogle Scholar
• Lim SY, Bauermeister A, Kjonaas RA, Ghosh SK. Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J Immune Based Ther Vaccines 2006;4:5
   PubMedGoogle Scholar
• Ghosh SK. Inventor. Phytol derived immunoadjuvants and their use in vaccine formulations. US8088395; 2012
   Google Scholar
• Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009;27(12):1787-96
   PubMed Web of Science ®Google Scholar
• Clapp T, Siebert P, Chen D, Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci 2011;100(2):388-401
   PubMed Web of Science ®Google Scholar
• Jones LS, Peek LJ, Power J, Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005;280(14):13406-14
   PubMed Web of Science ®Google Scholar
• Braun LJ, Eldridge AM, Cummiskey J, The role of adjuvant in mediating antigen structure and stability. J Pharm Sci 2012;101(4):1391-9
   PubMed Web of Science ®Google Scholar
• Harrington LE, Janowski KM, Oliver JR, Memory CD4 T cells emerge from effector T-cell progenitors. Nature 2008;452(7185):356-60
   PubMed Web of Science ®Google Scholar
• Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 2008;8(2):107-19
   PubMed Web of Science ®Google Scholar
• Harris SJ, Woodrow SA, Gearing AJ, The effects of adjuvants on CTL induction by V3:ty-virus-like particles (V3-VLPs) in mice. Vaccine 1996;14(10):971-6
   PubMed Web of Science ®Google Scholar
• Wuorimaa T, Dagan R, Vakevainen M, Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001;184(9):1211-15
   PubMed Web of Science ®Google Scholar
• Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008;38(8):2085-9
   PubMed Web of Science ®Google Scholar
• Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181(1):17-21
   PubMed Web of Science ®Google Scholar
• Calabro S, Tortoli M, Baudner BC, Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011;29(9):1812-23
   PubMed Web of Science ®Google Scholar
• Brewer JM, Conacher M, Satoskar A, In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26(9):2062-6
   PubMed Web of Science ®Google Scholar
• Bungener L, Geeraedts F, Ter Veer W, Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008;26(19):2350-9
   PubMed Web of Science ®Google Scholar
• Brewer JM, Conacher M, Hunter CA, Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999;163(12):6448-54
   PubMed Web of Science ®Google Scholar
• Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat Immunol 2006;7(5):449-55
   PubMed Web of Science ®Google Scholar
• Butler NR, Voyce MA, Burland WL, Hilton ML. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J 1969;1(5645):663-6
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993;11(9):914-8.
   PubMed Web of Science ®Google Scholar
• Blaylock RL. Aluminum induced immunoexcitotoxicity in neurodevelopmental and neurodegenerative disorders. Curr Inorg Chem 2012;2:1
   Google Scholar
• Migita K, Ueda-Nakata R, Masuda T, Macrophagic myofascitis associated with rheumatoid arthritis. Rheumatol Int 2010;30(7):987-9
   PubMed Web of Science ®Google Scholar
• Seubert A, Calabro S, Santini L, Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci 2011;108(27):11169-74
   PubMed Web of Science ®Google Scholar
• Wu J, Wang F, Fang F, Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. Arch Virol 2011;156(3):387-95
   PubMed Web of Science ®Google Scholar
• Barbro C, Carlson ÅMJ, Larsson A, The endogenous adjuvant squalene can induce a chronic t-cell-mediated arthritis in rats. Am J Pathol 2000;156(6):2057-65
   PubMed Web of Science ®Google Scholar
• Frey S. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003;21(27-30):4234-7
   PubMed Web of Science ®Google Scholar
• Medzhitov R. CpG DNA: security code for host defense. Nat Immunol 2001;2(1):15-16
   PubMed Web of Science ®Google Scholar
• Yi A-K, Tuetken R, Redford T, CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998;160(10):4755-61
   PubMed Web of Science ®Google Scholar
• Hcker G, Redecke V, Hcker H. Activation of the immune system by bacterial CpG-DNA. Immunology 2002;105(3):245-51
   PubMed Web of Science ®Google Scholar
• Millan CLB, Weeratna R, Krieg AM, CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci 1998;95(26):15553-8
   PubMed Web of Science ®Google Scholar
• Zorro S, Arias M, Riano F, Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus 2009;18(8):718-26
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004;24(6):693-701
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Hayashi T. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. Lupus 2003;12(11):838-45
   PubMed Web of Science ®Google Scholar
• Mikloska Z, Rückholdt M, Ghadiminejad I, Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-γ and IL-12 production. J Immunol 2000;164(10):5167-76
   PubMed Web of Science ®Google Scholar
• Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011;10(4):471-86
   PubMed Web of Science ®Google Scholar
• Cekic C, Casella CR, Eaves CA, Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 2009;284(46):31982-91
   PubMed Web of Science ®Google Scholar
• Trumpfheller C, Caskey M, Nchinda G, The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008;105(7):2574-9
   PubMed Web of Science ®Google Scholar
• Ngoi SM, Tovey MG, Vella AT. Targeting Poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-α/β. J Immunol 2008;181(11):7670-80
   PubMed Web of Science ®Google Scholar
• Miyake T, Kumagai Y, Kato H, Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009;183(4):2522-8
   PubMed Web of Science ®Google Scholar
• Kumar H, Koyama S, Ishii KJ, Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 2008;180(2):683-7
   PubMed Web of Science ®Google Scholar
• Robinson RA DV, Levy HB, Baron S, A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976;57(3):599-602
   PubMedGoogle Scholar
• Coughlin RT FA, Chu C, White AC, Winston S. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines. Vaccine 1995;13(1):17-21
   PubMed Web of Science ®Google Scholar
• Newman MJ, Wu JY, Gardner BH, Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol 1992;148(8):2357-62
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27(33):4388-401
   PubMed Web of Science ®Google Scholar
• Reimer JM, Karlsson KH, Lovgren-Bengtsson K, Matrix-m adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PloS One 2012;7(7):e41451
   PubMed Web of Science ®Google Scholar
• Kim YJ, Wang P, Navarro-Villalobos M, Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J Am Chem Soc 2006;128(36):11906-15
   PubMed Web of Science ®Google Scholar
• Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 2007;8(3):153-61
   PubMedGoogle Scholar
• Rook GAW. New meanings for an old word: adjuvanticity, cytokines and T cells. Immunol Today 1993;14(2):95-6
   PubMedGoogle Scholar